Opinion|Videos|July 15, 2024
Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study
Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- For a patient who does not receive second-line cellular therapy whether based on logistical or clinical reasons, what would be your choice of approved therapies?
- When choosing a second-line therapy for a patient not eligible for transplant or CAR T-cell therapy, what most impacts your decision? Drug approval? NCCN guidelines? Based on what first-line treatment was received?
- Please review the final 5-year data of the L-MIND study evaluating tafasitamab + lenalidomide.
Advertisement
Related to this article
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5